FDA greenlights Revolution Medicines' Rasonque for advanced pancreatic cancer

The FDA has granted approval to Revolution Medicines' new oral therapy, Rasonque, for patients with metastatic pancreatic cancer who have already received treatment or cannot tolerate combination chemotherapy. In a pivotal Phase III study, the drug more than doubled overall survival compared with standard care.

Why the approval matters

Pancreatic cancer remains one of the deadliest malignancies, with the American Cancer Society estimating over 67,000 new cases in the United States this year. Existing options rely heavily on aggressive chemotherapy, which often brings severe side‑effects and limited benefit. By directly inhibiting multiple forms of the RAS protein, a driver of tumour growth in many pancreatic tumours, Rasonque offers a targeted approach that not only extends life but also improves quality of life.

Patients already accessing the drug through the FDA’s compassionate‑use programme have reported noticeable relief. Barbara Andes, an 88‑year‑old from Fullerton, California, began the pill in July after a year of chemotherapy. She says the treatment let her resume everyday activities with far less nausea and fatigue.

"It's going to open this door now commercially for so many, many more people who are suffering," Andes said.

How Rasonque works

Rasonque is a once‑daily tablet that blocks several RAS isoforms, curbing the signalling pathways that fuel tumour proliferation. The drug is priced at $39,800 for a 30‑day supply, with the company pledging patient‑assistance programmes to mitigate cost barriers.

Mark Goldsmith, chief executive of Revolution Medicines, hailed the decision as validation of more than a decade of research into RAS‑driven disease. "This approval validates more than a decade of work aimed at pancreatic cancer, primarily RAS‑driven disease, and one of the most difficult challenges in medicine, cancer biology, and drug discovery," he said.

Investors responded positively, with the company's share price climbing 166 % this year, though it steadied at $211.70 following the announcement. Analysts at RBC Capital Markets project US sales could reach $28 million in the third quarter and $148 million by year‑end, while long‑term forecasts suggest the drug could generate up to $11.5 billion in annual global revenue.

Clinical leaders are optimistic about the broader impact. Rachna Shroff, chief of haematology and oncology at the University of Arizona Cancer Center, called the development "just the tip of the iceberg" for RAS‑targeted therapies. Peter Hosein, associate director for clinical research at the Pancreatic Cancer Research Institute, described the approval as a paradigm shift, noting that patients stayed on Rasonque longer than on conventional chemotherapy.

With the drug now commercially available, the next steps include expanding real‑world data collection, exploring combination regimens, and potentially extending the indication to earlier stages of the disease. If the early uptake mirrors trial results, Rasonque could reshape treatment standards and spur further investment in RAS inhibition research.